Class 2 drug alert, action within 48 hours, patient level recall esmya 5mg tablets (ulipristal acetate)

Following the PRAC recommendation, Esmya is being recalled, and the market authorisation suspended whilst a safety review is being conducted following reports of liver failure requiring liver transplant. Patients supplied Esmya are to be contacted to ask them to stop taking it.


Medicines and Healthcare products Regulatory Agency